Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05821101 · ClinicalTrials.gov registry record · NA
Clinical Outcomes of Clareon Vivity Intraocular Lens With Mini-Monovision Approach
A NA study of Aphakia, Postcataract, sponsored by Debbie S. Kuo, MD.
- Active
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05821101 is a NA study of Aphakia, Postcataract that is active but no longer recruiting, run by Debbie S. Kuo, MD. The registered enrollment target is 30 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05821101, a NA study of Aphakia, Postcataract, is active but no longer recruiting, sponsored by Debbie S. Kuo, MD.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Purpose is to study the clinical outcomes of Clareon Vivity and Clareon Vivity Toric intraocular lens (IOL) implants in patients who are planning to have cataract surgery in both eyes with a mini-monovision approach.
Conditions Studied
Interventions
- DEVICE Clareon Vivity and Clareon Vivity Toric IOLs targeted for mini-monovision with dominant eye set at emmetropia and non-dominant eye at -0.50.
Study Locations (1)
California
- Palo Alto Medical Foundation - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-04-06 |
| Est. Completion | 2026-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05821101
The ClinicalTrials.gov registry entry for NCT05821101 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Debbie S. Kuo, MD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Aphakia, Postcataract appearing as the primary indexed condition, and to 1 intervention - of which Clareon Vivity and Clareon Vivity Toric IOLs targeted for mini-monovision with dominant eye set at emmetropia and non-dominant eye at -0.50. is the first listed.
NCT05821101 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05821101 about?
NCT05821101 is a clinical study titled "Clinical Outcomes of Clareon Vivity Intraocular Lens With Mini-Monovision Approach". Purpose is to study the clinical outcomes of Clareon Vivity and Clareon Vivity Toric intraocular lens (IOL) implants in patients who are planning to have cataract surgery in both eyes with a mini-monovision approach.
What is the current status of trial NCT05821101?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2023-04-06. Estimated completion is 2026-06.
What conditions does trial NCT05821101 study?
This clinical trial studies the following conditions: Aphakia, Postcataract.
What interventions are being tested in trial NCT05821101?
The interventions under investigation include: Clareon Vivity and Clareon Vivity Toric IOLs targeted for mini-monovision with dominant eye set at emmetropia and non-dominant eye at -0.50. (DEVICE).
Who is sponsoring clinical trial NCT05821101?
This trial is sponsored by Debbie S. Kuo, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05821101 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.